by 
The cancer vaccines market comprises preventive vaccines that aid in lowering the risk of developing certain types of cancers and therapeutic vaccines which help in treating existing cancers by stimulating or restoring the ability of the immune system to fight cancer cells. Cancer vaccines work by recognizing tumor-specific or tumor-associated antigens that differentiate cancer cells from normal cells. They help induce an immune response by activating several types of immune cells such as T cells, B cells and macrophages.
The Global cancer vaccines market is estimated to be valued at US$ 1.9 Bn in 2024 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the cancer vaccines market are Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd. These players are focusing on the development of personalized cancer vaccines tailored to an individual’s specific tumor mutations which is expected to drive market growth.
The key opportunities in the market include rise in cancer incidence, increasing demand for therapeutic and preventive vaccines against HPV infections and lung cancer. According to WHO, cancer burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040.
Advancements in vaccine design such as antigen identification and genome sequencing techniques are allowing development of personalized cancer vaccines. Combination of cancer vaccines with immune checkpoint inhibitors is also demonstrating improved clinical outcomes.
Market drivers
The high market growth rate can be attributed to increasing expenditure on cancer R&D, rising demand for personalized medicine and growing popularity of combination therapies. According to PhRMA, the pharmaceutical industry invested an estimated $83 billion in R&D in 2021 which is fueling innovations in cancer vaccines. The need for improved treatment outcomes and demand for targeted therapies from patients are also expected to propel the cancer vaccines market during the forecast period.
Current challenges in Cancer Vaccines Market:
The cancer vaccines market faces several challenges which restrict its growth. The development of cancer vaccines requires immense investments and has a lengthy approval process. This high development cost makes it difficult for smaller players to compete in this market. Identifying the appropriate cancer-causing antigens is also a challenge. The specific antigen which triggers an immune response varies from patient to patient based on their genetic makeup. This poses challenge in developing broadly effective cancer vaccines. Some types of cancers are also more difficult to treat than others using vaccines alone as these cancer types may have already metastasized or may not be immunogenic. Addressing these challenges would help realize the true market potential of cancer vaccines.
SWOT Analysis
Strength: Cancer vaccines offer potential benefits of being long lasting and possibly preventing various cancer types. They enable training of immune cells to recognize and attack cancer cells specifically.
Weakness: High development costs and lengthy approval process makes it challenging for smaller players. Difficulty in identifying universally applicable cancer antigens.
Opportunity: Rapid advancements in cancer research and immunotherapies are improving understanding of cancer biology. This helps in developing more effective antigens andadjuvants. Growing cancer burden worldwide indicates a large market opportunity.
Threats: Entry of generic versions and biosimilars once blockbuster drugs lose patent poses pricing pressure. Side effects and safety concerns can impact product uptake.
Geographical regions with high market value currently include North America and Europe due to advanced healthcare systems and higher acceptance of premium therapies. However, the Asia Pacific region is fastest growing market for cancer vaccines driven by factors like rising healthcare spending, large patient pools and increasing focus on new treatments in countries like China and India.
The North American region currently has the largest market share in the cancer vaccines market owing to developed healthcare infrastructure, high adoption of premium cancer therapies and presence of leading global players. The US market particularly has witnessed rapid uptake of newer vaccines due to supportive regulatory framework and reimbursement policies. However, the Asia Pacific region is poised to showcase fastest growth over the forecast period. This can be attributed to expanding healthcare infrastructure, growing disposable incomes, increasing focus on new treatment options and rising cancer incidence rates across densely populated countries of China and India.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
